Logo image of FULC

FULCRUM THERAPEUTICS INC (FULC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FULC - US3596161097 - Common Stock

11.29 USD
+0.23 (+2.08%)
Last: 11/21/2025, 8:00:01 PM
11.27 USD
-0.02 (-0.18%)
After Hours: 11/21/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to FULC. FULC was compared to 192 industry peers in the Pharmaceuticals industry. While FULC has a great health rating, there are worries on its profitability. FULC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FULC had negative earnings in the past year.
FULC had a negative operating cash flow in the past year.
In the past 5 years FULC always reported negative net income.
In the past 5 years FULC always reported negative operating cash flow.
FULC Yearly Net Income VS EBIT VS OCF VS FCFFULC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

FULC has a better Return On Assets (-4.53%) than 71.88% of its industry peers.
The Return On Equity of FULC (-4.90%) is better than 76.56% of its industry peers.
Industry RankSector Rank
ROA -4.53%
ROE -4.9%
ROIC N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
FULC Yearly ROA, ROE, ROICFULC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FULC Yearly Profit, Operating, Gross MarginsFULC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

9

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
FULC has less shares outstanding than it did 1 year ago.
The number of shares outstanding for FULC has been increased compared to 5 years ago.
FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FULC Yearly Shares OutstandingFULC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FULC Yearly Total Debt VS Total AssetsFULC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

FULC has an Altman-Z score of 19.64. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.
FULC's Altman-Z score of 19.64 is amongst the best of the industry. FULC outperforms 91.15% of its industry peers.
FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.64
ROIC/WACCN/A
WACC8.75%
FULC Yearly LT Debt VS Equity VS FCFFULC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 17.70 indicates that FULC has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.70, FULC belongs to the best of the industry, outperforming 88.02% of the companies in the same industry.
A Quick Ratio of 17.70 indicates that FULC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 17.70, FULC belongs to the best of the industry, outperforming 88.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.7
Quick Ratio 17.7
FULC Yearly Current Assets VS Current LiabilitesFULC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

FULC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -280.65%.
Looking at the last year, FULC shows a very strong growth in Revenue. The Revenue has grown by 2752.05%.
The Revenue has been growing by 61.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-280.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -27.38% on average over the next years. This is quite bad
Based on estimates for the next years, FULC will show a decrease in Revenue. The Revenue will decrease by -8.96% on average per year.
EPS Next Y-440.72%
EPS Next 2Y-137.83%
EPS Next 3Y-71.19%
EPS Next 5Y-27.38%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-8.96%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FULC Yearly Revenue VS EstimatesFULC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
FULC Yearly EPS VS EstimatesFULC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FULC. In the last year negative earnings were reported.
Also next year FULC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FULC Price Earnings VS Forward Price EarningsFULC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FULC Per share dataFULC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as FULC's earnings are expected to decrease with -71.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-137.83%
EPS Next 3Y-71.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FULC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (11/21/2025, 8:00:01 PM)

After market: 11.27 -0.02 (-0.18%)

11.29

+0.23 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners101.13%
Inst Owner Change-1.56%
Ins Owners0.63%
Ins Owner Change0%
Market Cap611.01M
Revenue(TTM)80.00M
Net Income(TTM)-9.72M
Analysts80
Price Target13.9 (23.12%)
Short Float %6.62%
Short Ratio5.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.94%
Min EPS beat(2)-3.46%
Max EPS beat(2)5.34%
EPS beat(4)3
Avg EPS beat(4)3.49%
Min EPS beat(4)-3.46%
Max EPS beat(4)6.63%
EPS beat(8)7
Avg EPS beat(8)870.55%
EPS beat(12)10
Avg EPS beat(12)583.7%
EPS beat(16)12
Avg EPS beat(16)438.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)23.06%
PT rev (3m)23.06%
EPS NQ rev (1m)-6.89%
EPS NQ rev (3m)-9.2%
EPS NY rev (1m)-1.97%
EPS NY rev (3m)0.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.64
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.48
BVpS3.67
TBVpS3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.53%
ROE -4.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.34%
Cap/Sales 0.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.7
Quick Ratio 17.7
Altman-Z 19.64
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)40.72%
Cap/Depr(5y)49.27%
Cap/Sales(3y)16.46%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-280.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y-440.72%
EPS Next 2Y-137.83%
EPS Next 3Y-71.19%
EPS Next 5Y-27.38%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-8.96%
EBIT growth 1Y82.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.85%
EBIT Next 3Y-40.78%
EBIT Next 5YN/A
FCF growth 1Y31.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.4%
OCF growth 3YN/A
OCF growth 5YN/A

FULCRUM THERAPEUTICS INC / FULC FAQ

What is the fundamental rating for FULC stock?

ChartMill assigns a fundamental rating of 4 / 10 to FULC.


Can you provide the valuation status for FULCRUM THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FULCRUM THERAPEUTICS INC (FULC). This can be considered as Overvalued.


Can you provide the profitability details for FULCRUM THERAPEUTICS INC?

FULCRUM THERAPEUTICS INC (FULC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for FULC stock?

The Earnings per Share (EPS) of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -440.72% in the next year.